Ciprofloxacin Injection Infusion Medicine 100ml: 200mg

China Ciprofloxacin Injection Infusion Medicine 100ml: 200mg, Find details about China Ciprofloxacin, Injection from Ciprofloxacin Injection Infusion Medicine 100ml: 200mg

Model NO.
100ml: 200mg
HS Code
3004909099
Model NO.
100ml: 200mg
HS Code
3004909099
Ciprofloxacin Injection/ Infusion

Name: Ciprofloxacin Lactate Injection(100ml:200mg)
Structural formula: C17H18FN3O3.C3H3O3
Mol wt: 421.43
Description the product is colorless or almost colorless pellucid liquid.
Pharmacology and toxicity
Broad spectrum aerobicidal quinolone antibiotic. In vitro ciprofloxacin lactate can resist all of the G- Bacteria effectively. It also has effect on the resistance of G+ Bacteria. But it has lower sensibility for the anaerobic bacteria. As a kind of bactericidal agent, ciprofloxacin can inhibit DNA screw enzyme, preventing them from the metabolism, and lead to bacteria dead.
Pharmacokinetics
After administering by intravenous drip 0.2g or 0.4g, the plasma peak concentration(Cmax) is 2.1μg/ml and 4.6μg/ml respectively. The medicine distributes widely to all kinds of tissues and body liquids(including cerebrospinal fluid), the concentration in the tissues usually exceed the concentration in the plasma. The binding rate with protein is about 20%~40%. 50%~70% of Ciprofloxacin Lactate is excreted, about 15% of the medicine is excreted as metabolism and a large amount of the medicine is excreted in bile and dejection.
Disease treated  
Used for the treatment of :
1.Urinary tract infections
2.Respiratory tract infections
3.Gastrointestinal infections
4.Typhia
5.Bone & joint infections
6.Skin & soft Tissue infections

7.General infection including blood poisoning


Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.  
The products have been sold to some countries and regions in South America, Africa, and Asia.